147 related articles for article (PubMed ID: 16961582)
1. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.
Vehreschild JJ; Krüger K; Kurzai O; Wickenhauser C; Behringer K; Töx U; Cornely OA
Mycoses; 2006; 49 Suppl 1():42-7. PubMed ID: 16961582
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.
Mullane K; Toor AA; Kalnicky C; Rodriguez T; Klein J; Stiff P
Transpl Infect Dis; 2007 Jun; 9(2):89-96. PubMed ID: 17461992
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
4. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
7. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation.
Gupta S; Almyroudis NG; Battiwalla M; Bambach BJ; McCarthy PL; Proefrock AD; Ball D; Paplham P; Varma A; Kwon-Chung J; Segal BH
Transpl Infect Dis; 2007 Jun; 9(2):156-60. PubMed ID: 17462004
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
[TBL] [Abstract][Full Text] [Related]
11. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
12. Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Fanci R; Pini G; Bartolesi AM; Pecile P
Rev Iberoam Micol; 2013 Jan; 30(1):51-3. PubMed ID: 22659590
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation.
Mousset S; Bug G; Heinz WJ; Tintelnot K; Rickerts V
Transpl Infect Dis; 2010 Jun; 12(3):261-4. PubMed ID: 19954497
[TBL] [Abstract][Full Text] [Related]
14. Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection.
Lebeau O; Van Delden C; Garbino J; Robert J; Lamoth F; Passweg J; Chalandon Y
Transpl Infect Dis; 2010 Jun; 12(3):269-72. PubMed ID: 20163567
[TBL] [Abstract][Full Text] [Related]
15. Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation.
Ustun C; DeRemer DL; Steele JC; Forseen C; Fisher JF; Jillella AP
Int J Antimicrob Agents; 2008 Oct; 32(4):365-6. PubMed ID: 18572390
[No Abstract] [Full Text] [Related]
16. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
17. [Candidiasis of the liver following successful chemotherapy of acute myeloid leukemia (Fab type 6) and recovery with oral fluconazole therapy].
Keiser G; Schmid M; Ishak KG; Wirth W; Vogt M
Schweiz Med Wochenschr; 1996 Apr; 126(17):713-7. PubMed ID: 8668982
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole.
Bhattacharya M; Rajeshwari K; Dhingra B
J Postgrad Med; 2010; 56(2):163-7. PubMed ID: 20622401
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.
Störzinger D; Lichtenstern C; Swoboda S; Weigand MA; Hoppe-Tichy T
Mycoses; 2008 Sep; 51 Suppl 2():52-7. PubMed ID: 18721332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
